Skip to main content

29-04-2024 | Cardiomyopathy | Editor's Choice | News

ACC 2024

Ninerafaxstat shows early promise for treating nonobstructive hypertrophic cardiomyopathy

Author: Dr. Jonathan Smith

medwireNews: The cardiac mitotrope ninerafaxstat is well tolerated by patients with nonobstructive hypertrophic cardiomyopathy (nHCM), with early signs of improvements in exercise capacity and health status, a phase 2 trial suggests.

Related topics

Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine